ACRP-MDP Certification Sample Questions

The ACRP Medical Device Professional Certification Sample Question Set on this page is designed to familiarize you with the actual ACRP-MDP exam format and question types. These sample questions help you understand how questions are structured and what to expect on test day. While they provide a useful starting point, they represent only a limited preview of the real exam experience.

These sample questions are intended for evaluation and familiarization only. To understand exam style, pacing, and reasoning patterns more clearly, we recommend trying our online sample practice environment. If you are preparing for the ACRP Medical Device Professional (ACRP-MDP) and want to assess your readiness more rigorously, structured, timed, scenario-based practice is recommended. This approach aligns with the cognitive demands and professional expectations typically associated with medical device clinical research professionals, clinical operations professionals, regulatory and quality professionals working in settings such as medical device sponsors and manufacturers, contract research organizations, clinical research sites.

Try Sample Exam »    |    Access Full ACRP-MDP Practice Exam »

The demo introduces core concepts, while full-length premium simulations provide deeper, scenario-based coverage that more closely reflects the actual cognitive demands of the ACRP Medical Device Professional exam, particularly in areas such as medical device trial operations and site management, participant safety and device risk oversight, investigational device regulation and research design. You can use these sample questions as a starting point, then progress to the ACRP-MDP Certification Practice Exam for stronger readiness. Our premium simulations are designed to mirror real exam conditions, helping you refine reasoning, pacing, and decision-making before your official exam attempt.

ACRP-MDP Sample Questions:

01. A device shows a safety concern before approval and, separately, a different concern after it is approved and marketed.
Which statement about reporting across these periods is correct?
a) Reporting is required in neither period unless a participant files a complaint.
b) Reporting obligations exist only before approval and end once the device is marketed.
c) Safety reporting applies in both the pre-approval and post-approval periods.
d) Reporting obligations begin only after approval, during post-market use.

02. A newly identified serious risk of the investigational device emerges during an ongoing trial.
What is required for participants already enrolled?
a) Inform participants of the new risk only if they experience a related event.
b) Update consent with the new risk and re-consent the enrolled participants.
c) Note the risk in the study file and leave the enrolled participants uninformed.
d) Apply the new information only to participants enrolled after the risk was identified.

03. A participant's compliance with a home-use device appears low based on device-usage data.
Which management response is appropriate?
a) Discuss and re-instruct the participant, document it, and assess data impact.
b) Take no action as long as the participant continues to attend visits.
c) Record the participant as compliant to keep the site's compliance rate high.
d) Remove the participant's data because low compliance makes it unusable.

04. A site is preparing for a possible inspection and reviews its essential documents and device accountability.
Which approach best reflects genuine inspection readiness?
a) Create the missing records shortly before the inspection to present a complete file.
b) Focus only on the documents most likely to be requested and set the rest aside.
c) Rely on the sponsor to provide the site's records during the inspection.
d) Maintain complete, current, accurate records throughout, not last-minute.

05. A sponsor is developing a risk-management strategy for a first-in-human implantable device study where prior human data are limited.
Which strategy best reflects sound risk management for this design?
a) Treat the risks as minimal, taking the device's completed bench testing as sufficient.
b) Use staged enrollment, close monitoring, and pre-defined stopping rules.
c) Enroll the full planned study sample all at once.
d) Rely on a post-hoc analysis to identify the study's risks after the enrollment has already been completed.

06. Before a device study begins, the site must confirm that specialized equipment is fit for use.
Which step best supports this?
a) Assume the equipment is ready because it was used in a previous unrelated study.
b) Qualify and calibrate the equipment and document its readiness before use.
c) Rely on the manufacturer's delivery as sufficient confirmation of readiness.
d) Calibrate the equipment only after the first participant procedure is performed.

07. Which best describes the ethical principle of fair (equitable) participant selection in a device trial?
a) Selection is left to recruiter discretion without defined eligibility criteria.
b) Selection favors the most easily available population to speed up study enrollment.
c) Selection rests on scientific and safety criteria, not convenience or vulnerability.
d) Selection targets vulnerable groups because they are more likely to agree to enroll.

08. In a device study enrolling adolescents, the protocol requires both a parent's or guardian's consent and the adolescent's participation.
Which combination correctly reflects the ethical requirement for these minors?
a) Both consent and assent are set aside for these minors whenever the study is judged to be of minimal risk.
b) The parent's consent alone is obtained, and the adolescent's own views are treated as an optional consideration.
c) The adolescent provides consent for herself, and the parent is simply informed of the enrollment decision afterward.
d) The representative consents, and the adolescent gives capacity-appropriate assent.

09. A site needs to manage the return of recalled investigational devices from participants who use them at home.
Which approach best maintains accountability and participant safety during the recall return?
a) Identify affected participants, arrange safe return, and document disposition.
b) Collect the returned units while leaving out any record of which participant returned each particular device.
c) Ask the participants to discard the recalled units at home and then skip the return records for those units.
d) Delay the recall return of the units until the participant's final scheduled study visit.

10. A coordinator must distinguish a protocol deviation from a protocol violation after a scheduling error in a device trial.
Which distinction is correct?
a) Deviations and violations are identical terms with no meaningful difference.
b) A deviation is more serious than a violation and always requires expedited reporting.
c) A violation is a deviation affecting rights, safety, or data; not every one is.
d) Every protocol deviation is automatically a protocol violation regardless of its impact.

Answers:

For full-length, timed, scenario-based practice aligned with the official exam framework - and to build pacing, consistency, and confidence - explore our Premium ACRP-MDP Certification Practice Exam.

Note: These sample questions are not official exam questions and are intended only for familiarization and study purposes. If you find any typos or data entry errors in these ACRP Medical Device Professional (ACRP-MDP) sample questions, please let us know by emailing us at feedback@medicoexam.com